



10145-1632

AUG 15 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Curiel & Reynolds

§ ART UNIT: RECEIVED

FILED: February 14, 2002

§ § AUG 20 2002

SERIAL NO.: 10/075,322

§ EXAMINER:

FOR: Combined Transductional and
Transcriptional Targeting System
For Improved Gene Delivery§ DOCKET:
§ D 6392

Honorable Commissioner of Patents
Box DD
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

Dear Sir:

I hereby certify under 37 CFR 1.8 that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to: Honorable Commissioner of Patents, BOX DD, Washington, DC 20231.

- 1) Information Disclosure Statement;
- 2) Information Disclosure Statement Cover Letter;
- 3) PTO Form 1449 (Six References cited); and
- 4) Postcard.

Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Benjamin Aaron Adler, Ph.D., J.D.

Counsel for Applicant
Registration No. 35,423

Date: Aug 12, 2002
ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
(713) 270-5391
BADLER1@houston.rr.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Curiel & Reynolds

FILED: February 14, 2002

SERIAL NO.: 10/075,322

FOR: Combined Transductional and Transcriptional Targeting System For Improved Gene Delivery

ART UNIT:

卷之三

EXAMINER:

RECEIVED

All rights reserved.

TECH CENTER 1600/2900

DOCKET:
D6392

Honorable Commissioner of Patents
Box DD
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)
AND STATEMENT UNDER 37 CFR 1.97(e)(1)

Dear Sir:

Enclosed herewith for filing under 37 C.F.R. 1.97(c) in the above-referenced matter is form PTO-1449 together with copies of the references listed therein. Applicants state that each item of information contained in the information disclosure statement herein was cited in a communication from a foreign application not more than three months prior to the filing of the information disclosure statement. If any questions remain, the Examiner is respectfully requested to call the undersigned attorney at (713)-270-5391.

Respectfully submitted,

Date: May 12, 2002
ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
(713) 270-5391
BADLER1@houston.rr.com

Benjamin Aaron Adler, Ph.D., J.D.
Counsel for Applicant
Registration No. 35,423



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Information Disclosure Statement

DOCKET NO.: D6392
SERIAL NO.: 10/075,322
APPLICANT: Curiel & Reynolds
FILING DATE: February 14, 2002
GROUP:

RECEIVED

AUG 20 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
	5,871,727	2/16/99	Curiel	424/93.2	514/44	12/6/96
	5,846,782	12/8/98	Wickham	435/697	530/350	8/21/96
	5,837,283	11/17/98	McDonald	424/450	935/54	3/12/97

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Publication: Patent Cooperation Treaty (PCT)

Translation: English

Document Number: WO 99/36545 Date: 7/22/99 ✓

Country: Great Britain

Class Or Subclass C12N 15/86

Patent: Yes No

Title: Adenoviral Vectors With Modified Capsid Proteins

OTHER DOCUMENTS (Including Author, Title, Place of Date, Publication)

a. Reynolds, P. et al. *Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo.* Nature Biotechnology, vol. 19, 2001, pp. 838-842.

b. Muzykantov, Vladimir R. *Endothelial cells internalize monoclonal antibody to angiotensin-converting enzyme.* American Physiological Society, 1996, pp. L704-L713

Examiner

Date Considered

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)